Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.61 |
| ▸ | TUBB | P07437 | 1/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.61 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.61 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.61 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.61 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.61 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471006 | 1.00 | RELA (0.69) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL7194475 | 1.00 | RELA (0.69) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL31317665 | 0.89 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700056 | 0.89 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700055 | 0.89 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL23158820 | 0.89 | RELA (0.84) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL15932972 | 0.86 | RELA (0.62) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL14401251 | 0.83 | RELA (0.81) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700797 | 0.83 | RELA (0.81) | RELANFE2L2CYP19A1NQO2TUBB4A | |
| SCHEMBL700798 | 0.83 | RELA (0.81) | RELANFE2L2CYP19A1NQO2TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-11739354-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-08-29 | — | — | US | disclosed |
| EP-2822938-B1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RES NEW ZEALAND LIMITED (NZ) | 2019-07-03 | — | — | EP | disclosed |
| US-20180011405-A1 | RESIST UNDERLAYER FILM COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING RESIST UNDERLAYER FILM, AND COMPOUND FOR RESIST UNDERLAYER FILM COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-9670234-B2 | Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs | SCINOPHARM TAIWAN, LTD. (TW) | 2017-06-06 | — | — | US | disclosed |
| US-9670234-B2 | Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs | SCINOPHARM TAIWAN, LTD. (TW) | 2017-06-06 | — | — | US | disclosed |
| EP-3149135-A2 | PERFUME COMPOSITIONS | Givaudan S.A. (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN, LTD. (TW) | 2016-01-14 | — | — | US | disclosed |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN, LTD. (TW) | 2016-01-14 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070167505-A1 | Substituted benzimidazoles and their use for inducing apoptosis | BASILEA PHARMACEUTICA AG | 2007-07-19 | — | — | US | disclosed |
| US-20070167505-A1 | Substituted benzimidazoles and their use for inducing apoptosis | BASILEA PHARMACEUTICA AG | 2007-07-19 | — | — | US | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070066670-A1 | Substituted benzimidazoles and their use for inducing apoptosis | BASILEA PHARMACEUTICA AG | 2007-03-22 | — | — | US | disclosed |
| US-20070066670-A1 | Substituted benzimidazoles and their use for inducing apoptosis | BASILEA PHARMACEUTICA AG | 2007-03-22 | — | — | US | disclosed |
| US-4861742-A | Bifunctional alkali metal compounds, preparation and use thereof as polymerization initiators | BASF AKTIENGESELLSCHAFT (DE) | 1989-08-29 | — | — | US | disclosed |
| EP-0143952-A1 | Substituted cinnamyl-2,3-dihydrobenzopyrans and cinnamylphenols useful as anti-inflammatory agents | MERCK & CO. INC. (US) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | RELA 1097/4885NFE2L2 1887/4885CYP19A1 3741/4885 |
| US-20070167505-A1 | Substituted benzimidazoles and their use for inducing apoptosis | BAX, BCL2, BAD | RELA 496/4885NFE2L2 439/4885CYP19A1 607/4885 |
| US-20070066670-A1 | Substituted benzimidazoles and their use for inducing apoptosis | BAX, BCL2, BAD | RELA 496/4885NFE2L2 439/4885CYP19A1 607/4885 |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | PTGIS, PTGER1, PTGS1 | RELA 2631/4885NFE2L2 94/4885CYP19A1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.